Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis

Table 1

Characteristics of included studies.

AUTHORS; MAIN ANALYSIS	YEAR	COUNTRY	INCLUSION; CRITERION	AGE; MEAN; (RANGE)	N; TOTAL	N; BENIGN	N; CIN2+	N; CIN3+	DNA HRHPV TEST; (IF PRESENT)	MRNA HPV TEST	VERIFICATION BY HISTOPATHOLOGY
ALAGHEHBANDAN ET AL.	2013	Canada	abnormal cytology	30.7	1289	929	360	NI	HC2	PreTect HPV-Proofer	Partial
ANDERSSON ET AL.	2006	Sweden	abnormal cytology	35.3; (23-60)	71	32	39	22	RT-PCR	NucliSens EasyQ HPV	complete
BENEVOLO ET AL.	2011A	Italy	HSIL in cytology	39.5; (18-83)	139	105	34	NI	HC2 or PCR; (HPV MX BIO)	PreTect HPV-Proofer	Partial
BINNICKER ET AL.	2014	USA	abnormal cytology	NI	370	289	81	41	HC2	Aptima	complete
CASTLE ET AL.	2007	USA	ASC-US in cytology	NI	531	426	105	54	HC2	Aptima	complete
CASTLE ET AL.	2015	US and England	ASC-US in cytology	34.2; (21-28)	713	634	79	33	none	Aptima	complete
CATTANI ET AL.	2009	Italy	not specified	35 (20-77)	143	84	59	41	HC2	NucliSens EasyQ HPV	complete
CHERNESKY ET AL.	2017	Canada and USA	abnormal cytology or DNA+	36.1; (21-80)	1350	1203	147	71	COBAS4800	Aptima	complete
CLAD ET AL.	2011	Germany	abnormal cytology	NI	424	172	252	163	HC2	Aptima	Partial
COQUILLARD ET AL.	2011	USA and Spain	not specific	NI	217	187	73	30	HC2	OncoTect	complete
CUSCHIERI ET AL.	2013	UK	abnormal cytology	29.3; (25-38)	1366	987	379	175	HC2	Aptima	Partial
CUZICK ET AL.	2013	UK	abnormal cytology	37 (20-66)	119	79	40	19	HC2	Aptima/PreTect HPV Proofer	complete
DOCKTER ET AL.	2009	USA	not specified	NI	753	612	141	87	HC2	Aptima	Partial
DUVLIS ET AL.	2015	Republic of Macedonia	not specific	(19-78)	61	32	29	NI	PCR	NucliSens EasyQ HPV	Partial
EVANS ET AL.	2014	USA	Any CIN in histopathological	28.8; (17-57)	86	32	54	32	CISH	RNA scope 2.0 (CISH)	Partial
GALAROWICZ ET AL.	2012	Poland	not specified	37,8; (19-81)	85	49	36	NI	HC2	NucliSens EasyQ HPV	Partial
GE ET AL.	2017	USA	not specified	NI	175	146	29	NI	none	Aptima	complete
GE ET AL.	2018	USA	not specified	NI	603	500	103	NI	none	Aptima	complete
GUO ET AL.	2014	China	ASC-US/ LSIL	34 (21-69)	411	339	72	17	HC2	Aptima	complete
HALFON ET AL.	2010	France	abnormal cytology	38 18-77	112	75	37	NI	HC2	NucliSens EasyQ HPV	Partial
HOVLAND ET AL.	2010	Norway, Belgium, Sweden, Congo, Netherlands	not specific	37 (25-60)	313	297	16	NI	PCR	PreTect HPV-Proofer	complete
IFTNER ET AL.	2015	Germany	abnormal cytology, mRNA+ or DNA+	(30-60)	603	513	90	43	HC2	Aptima	complete
JOHANSSON ET AL.	2015	Sweden	ASC-US/ LSIL	42 (35-68)	342	236	106	43	none	Aptima	complete
KOILOPOULOS ET AL	2012	Greece	ASC-US/ LSIL	38	79	37	42	12	none	NucliSens EasyQ HPV and OncoTect	Partial
KOTTARDI ET AL.	2011	Greece	abnormal cytology	(21-65)	189	146	43	16	PCR (CLART2)	OncoTect	Partial
LI ET AL.	2017	China	ASC-US in cytology	NI	189	121	68	33	HC2	Quantivirus	complete
LIE ET AL.	2005	Norway	abnormal cytology	35 (19-85)	383	92	291	NI	HC2	PreTect HPV-Proofer	complete
LIU ET AL.	2014	China	abnormal cytology or DNA+	NI	92	35	57	56	Quantivirus	Quantivirus	Partial
LIU ET AL.	2017	China	ASC-US in cytology	>30	312	159	153	79	none	Quantivirus	complete
MOLDEN ET AL.	2005	Norway	HSIL in cytology	48.9; (30-91)	23	9	14	NI	none	PreTect HPV Proofer	complete
MONSONEGO ET AL.	2011	France	abnormal cytology, mRNA+ or DNA+	(20-65)	1113	1012	101	27	HC2	Aptima	complete
MUANGTO ET AL.	2016	Thailand	abnormal cytology	96.4%>30 years	1362	1349	13	12	Cervista	Aptima	Partial
OLIVEIRA ET AL.	2013	Portugal	not specified	34.6; (18-73)	554	259	295	NI	HC2	NucliSens EasyQ HPV	Partial
OVESTAD ET AL.	2011	Norway, USA, China Netherlands	ASC-US/ LSIL	40 (25-69)	121	76	45	NI	COBAS4800	PreTect HPV-Proofer/ Aptima	complete
PADALKO ET AL.	2013	Belgium	ASC-US in cytology	NI	35	8	27	NI	PCR	NucliSens EasyQ HPV	complete
PEREZ CASTRO ET AL.	2013	Spain	HSIL in cytology	36.9; (20-71)	49	44	5	NI	none	NucliSENSEasyQ	Partial
PERSSON ET AL.	2014	Sweden	ASC-US/ LSIL	32.8	205	132	73	36	Linear Array	Aptima	complete
PIERRY ET AL.	2012	USA	abnormal cytology	46%>30	246	201	45	15	none	OncoTect	Partial
RATNAM ET AL.	2009	Canada	abnormal cytology	NI	831	591	240	NI	HC2	PreTect HPV-Proofer/ Aptima	complete
RATNAM ET AL.	2010	Canada	abnormal cytology	31 (15-80)	1551	1149	402	NI	HC2	PreTect HPV-Proofer	Partial
RATNAM ET AL.	2011	Canada	abnormal cytology	36.3; (16-81)	1418	1017	401	281	HC2	Aptima	Partial
REBOJI ET AL.	2014	Denmark	abnormal cytology	NI	259	140	119	84	HC2	Aptima	complete
REID ET AL.	2015	USA and UK	not specific	44.2; (30-89)	818	798	20	11	HC2	Aptima	Partial
REN ET AL.	2017	China	ASC-US in cytology	38.5; (19-68)	160	129	31	NI	HC2	Quantivirus	complete
REUSCHENBACH ET AL.	2010	Germany	abnormal cytology	36 (28-44)	237	73	164	110	HC2	Aptima	complete
SHEN ET AL.	2013	China	not specified	37 (16-77)	75	58	17	NI	HC2	Quantivirus	complete
SORBYE ET AL.	2011	Norway	LSIL in cytology	NI		297	228	69	none	PreTect HPV-Proofer	complete
STATHOPOULOU ET AL.	2014	Greece	not specified		1039	591	53	24	none	NASBA/ OncoTect	Partial
STOLER ET AL.	2013	US and England	ASC-US in cytology	31 (21-71)	740	649	91	41	HC2	Aptima	complete
SZAREWSKI ET AL.	2012	UK, USA and France	abnormal cytology	29 (26-35)	911	552	359	224	HC2	PreTect HPV-Proofer/ Aptima	complete
TROPÉ ET AL.	2009	Norway	HSIL+ in cytology	37 (17-76)	1379	736	643	508	Amplicor	PreTect HPV-Proofer	Partial
TROPÉ ET AL.	2012	Norway	ASC-US/ LSIL	39.6; (18-83)	665	565	100	60	Amplicor	PreTect HPV-Proofer	Partial
TUNEY ET AL.	2017	Turkey	abnormal cytology	42.4; (22-89)	25	15	NI	10	PCR	NucliSens EasyQ HPV	complete
VALASOULIS ET AL.	2014	UK	HSIL+ in cytology	37.8; (21-63)	189	100	89	NI	PCR (CLART2)	NASBA/ OncoTect	complete
VALENÇA ET AL	2015	Brazil	HSIL+ in cytology	35.3	111	39	72	NI	none	NucliSENSEasyQ	complete
VIRTANEN ET AL.	2016	Finland	abnormal cytology	(18-86)	330	263	67	NI	HC2	Aptima	complete
WALDSTROM ET AL.	2011	Denmark	ASC-US in cytology	42.2; (30-69)	169	121	48	27	Linear Array	Aptima	complete
WALDSTROM ET AL.	2013	Denmark	LSIL in cytology	32.3; (16-65)	469	382	87	46	none	Aptima	complete
WESTRE ET AL.	2016	Norway	ASC-US/ LSIL	39	162	126	36	NI	COBAS	PreTect HPV-Proofer	Partial
WOJCIECH ET AL.	2012	Poland	abnormal cytology, mRNA+ or DNA+	45 (25-65)	421	339	82	NI	COBAS4800	NucliSens EasyQ HPV	complete
WU ET AL.	2010	China and USA	abnormal cytology or DNA+	35 (25-59)	2000	1973	27	15	HC2	Aptima	complete

CIN: cervical intraepithelial neoplasia.
If the information was available, N total and N benign included CIN1. NI: not informed. Verification by histopathology: studies with partial verification only performed biopsy in women with colposcopy lesion.